| |
| |
|
| Insider
Information: |
Column Group Ii Gp, Lp |
| Relationship: |
10% Owner |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
800,000 |
|
|
Indirect Shares
|
1,000 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$1,540 |
|
|
| Total
Shares |
801,000 |
|
|
| Total
Value |
$1,540 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
59
|
0
|
|
Stock
price went up :
|
24
|
0
|
| Stock
price went down : |
35
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 -3.1%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Immune Design Corp. |
IMDZ |
10% Owner |
2016-09-20 |
800,000 |
|
0 |
Premium* |
|
|
Ngm Biopharmaceuticals Inc |
NGM |
10% Owner |
2024-04-05 |
0 |
2024-04-05 |
1,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-06-09 |
4 |
B |
$13.50 |
$13,286,174 |
I/I |
984,161 |
90,442 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-03-23 |
4 |
B |
$11.63 |
$1,981,601 |
D/D |
170,387 |
907,377 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-04-07 |
4 |
B |
$14.38 |
$1,779,209 |
D/D |
123,728 |
1,427,469 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-03-19 |
4 |
B |
$11.59 |
$1,720,698 |
D/D |
148,464 |
593,908 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-03-20 |
4 |
B |
$11.77 |
$1,684,075 |
D/D |
143,082 |
736,990 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-04-08 |
4 |
B |
$14.95 |
$1,683,400 |
D/D |
112,602 |
1,540,071 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-03-24 |
4 |
B |
$12.22 |
$1,568,767 |
D/D |
128,377 |
1,035,754 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-03-31 |
4 |
B |
$12.53 |
$1,479,380 |
D/D |
118,067 |
1,156,237 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-04-01 |
4 |
B |
$12.26 |
$1,447,501 |
D/D |
118,067 |
1,274,304 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-06-01 |
4 |
B |
$13.45 |
$1,237,400 |
I/I |
92,000 |
56,836 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-07-24 |
4 |
B |
$17.93 |
$1,232,670 |
D/D |
68,749 |
1,609,013 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-05-17 |
4 |
B |
$13.42 |
$1,194,779 |
I/I |
89,049 |
45,610 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2023-01-11 |
4 |
B |
$4.76 |
$994,840 |
I/I |
209,000 |
689,542 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
– – • |
2022-05-12 |
4 |
B |
$11.62 |
$966,678 |
I/I |
83,175 |
37,308 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
– – • |
2022-05-11 |
4 |
B |
$11.23 |
$935,354 |
I/I |
83,175 |
34,563 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
– – • |
2022-05-09 |
4 |
B |
$10.79 |
$897,699 |
I/I |
83,175 |
30,786 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
– – • |
2023-01-31 |
4 |
B |
$5.00 |
$883,403 |
I/I |
176,730 |
927,231 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-05-31 |
4 |
B |
$13.47 |
$832,267 |
I/I |
61,806 |
53,800 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-05-18 |
4 |
B |
$13.20 |
$827,224 |
I/I |
62,650 |
47,677 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-02-06 |
4 |
B |
$15.96 |
$716,604 |
D/D |
44,900 |
298,822 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-03-03 |
4 |
B |
$17.99 |
$697,256 |
D/D |
38,758 |
427,151 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-02-28 |
4 |
B |
$17.91 |
$676,998 |
D/D |
37,800 |
374,269 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-02-27 |
4 |
B |
$17.91 |
$607,077 |
D/D |
33,896 |
336,469 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-05-25 |
4 |
B |
$13.43 |
$581,624 |
I/I |
43,292 |
51,004 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-11-03 |
4 |
B |
$4.99 |
$519,107 |
I/I |
104,090 |
304,787 |
1.5 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
